Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
Kirkwood
John M
JM
Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA. kirkwoodjm@upmc.edu
Tarhini
Ahmad A
AA
Moschos
Stergios J
SJ
Panelli
Monica C
MC
D017024:Chemotherapy, Adjuvant / Q000191:economics / Q000706:statistics & numerical data; D018849:Controlled Clinical Trials as Topic / Q000706:statistics & numerical data; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000556:secondary; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D012306:Risk; D016019:Survival Analysis; D016896:Treatment Outcome
D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins